Increased PrLZ-mediated androgen receptor transactivation promotes prostate cancer growth at castration-resistant stage

Carcinogenesis

Volumn 34, Issue 2, 2013, Pages 257-267

  Li, Lei ^a   Xie, Hongjun ^a   Liang, Liang ^a   Gao, Ye ^a   Zhang, Dong ^a   Fang, Leiya ^b   Lee, Soo Ok ^b   Luo, Jie ^b   Chen, Xingfa ^a   Wang, Xinyang ^a   Chang, Luke S ^a   Yeh, Shuyuan ^b,c   Wang, Yuzhuo ^d   He, Dalin ^a   Chang, Chawnshang ^b,c  

^a XI'AN JIAOTONG UNIVERSITY   (China)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN RECEPTOR; ANTINEOPLASTIC AGENT; ASC J 9; LEUCINE ZIPPER PROTEIN; PROSTATE LEUCINE ZIPPER PROTEIN; PROSTATE SPECIFIC ANTIGEN; PROTEASOME; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANDROGEN DEPRIVATION THERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ARTICLE; CANCER GROWTH; CANCER INHIBITION; CARCINOGENICITY; CASTRATION RESISTANT PROSTATE CANCER; CELL STRAIN LNCAP; CONFORMATIONAL TRANSITION; CONTROLLED STUDY; DRUG EFFECT; HUMAN; HUMAN CELL; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN CONFORMATION; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SCID MOUSE; STABLE TRANSFECTION; TRANSACTIVATION; TUMOR PROMOTION;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CASTRATION; CELL NUCLEUS; CELL PROLIFERATION; CELLS, CULTURED; CERCOPITHECUS AETHIOPS; COS CELLS; CYTOPLASM; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLUTATHIONE TRANSFERASE; HUMANS; IMMUNOENZYME TECHNIQUES; IMMUNOPRECIPITATION; MALE; MICE; NEOPLASM PROTEINS; PROSTATIC NEOPLASMS; PROTEASOME ENDOPEPTIDASE COMPLEX; PROTEIN TRANSPORT; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ANDROGEN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; TRANSCRIPTIONAL ACTIVATION; TRANSPLANTATION, HETEROLOGOUS; TWO-HYBRID SYSTEM TECHNIQUES;

EID: 84873530895     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgs337     Document Type: Article

References (52)

1. Cutler,J.A. et al. (2006) Leading causes of death in the United States. JAMA, 295, 383-4; author reply 384.
2. Sim,H.G. et al. (2005) Changing demography of prostate cancer in Asia. Eur. J. Cancer, 41, 834-845.
3. Miyamoto,H. et al. (2004) Androgen deprivation therapy for prostate cancer: current status and future prospects. Prostate, 61, 332-353.
4. Chen,C.D. et al. (2004) Molecular determinants of resistance to antiandrogen therapy. Nat. Med., 10, 33-39.
5. Niu,Y. et al. (2010) Differential androgen receptor signals in different cells explain why androgen-deprivation therapy of prostate cancer fails. Oncogene, 29, 3593-3604.
6. Visakorpi,T. et al. (1995) In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat. Genet., 9, 401-406.
7. Marcelli,M. et al. (2000) Androgen receptor mutations in prostate cancer. Cancer Res., 60, 944-949.
8. Bergerat,J.P. et al. (2009) Pleiotropic functional properties of androgen receptor mutants in prostate cancer. Hum. Mutat., 30, 145-157.
9. Gregory,C.W. et al. (2001) Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Cancer Res., 61, 2892-2898.
10. Mohler,J.L. (2008) Castration-recurrent prostate cancer is not androgenindependent. Adv. Exp. Med. Biol., 617, 223-234.
11. Chmelar,R. et al. (2007) Androgen receptor coregulators and their involvement in the development and progression of prostate cancer. Int. J. Cancer, 120, 719-733.
12. Heinlein,C.A. et al. (2002) Androgen receptor (AR) coregulators: an overview. Endocr. Rev., 23, 175-200.
13. Yeh,S. et al. (1998) From estrogen to androgen receptor: a new pathway for sex hormones in prostate. Proc. Natl. Acad. Sci. U.S.A., 95, 5527-5532.
14. Miyamoto,H. et al. (1998) Promotion of agonist activity of antiandrogens by the androgen receptor coactivator, ARA70, in human prostate cancer DU145 cells. Proc. Natl. Acad. Sci. U.S.A., 95, 7379-7384.
15. Craft,N. et al. (1999) A mechanism for hormone-independent prostate cancer through modulation of androgen receptor signaling by the HER-2/neu tyrosine kinase. Nat. Med., 5, 280-285.
16. Papatsoris,A.G. et al. (2007) The power and promise of "rewiring" the mitogen-activated protein kinase network in prostate cancer therapeutics. Mol. Cancer Ther., 6, 811-819.
17. Guo,Z. et al. (2006) Regulation of androgen receptor activity by tyrosine phosphorylation. Cancer Cell, 10, 309-319.
18. Qiu,Y. et al. (1998) Requirement of ErbB2 for signalling by interleukin-6 in prostate carcinoma cells. Nature, 393, 83-85.
19. Wang,R. et al. (2004) PrLZ, a novel prostate-specific and androgen-responsive gene of the TPD52 family, amplified in chromosome 8q21.1 and overexpressed in human prostate cancer. Cancer Res., 64, 1589-1594.
20. Boutros,R. et al. (2004) The tumor protein D52 family: many pieces, many puzzles. Biochem. Biophys. Res. Commun., 325, 1115-1121.
21. Byrne,J.A. et al. (1996) Definition of the tumor protein D52 (TPD52) gene family through cloning of D52 homologues in human (hD53) and mouse (mD52). Genomics, 35, 523-532.
22. Li,L. et al. (2009) PrLZ expression is associated with the progression of prostate cancer LNCaP cells. Mol. Carcinog., 48, 432-440.
23. Zhang,D. et al. (2011) PrLZ protects prostate cancer cells from apoptosis induced by androgen deprivation via the activation of Stat3/Bcl-2 pathway. Cancer Res., 71, 2193-2202.
24. Yeh,S. et al. (1999) Differential induction of androgen receptor transactivation by different androgen receptor coactivators in human prostate cancer DU145 cells. Endocrine, 11, 195-202.
25. Wang,J. et al. (2007) Identification and characterization of the novel human prostate cancer-specific PC-1 gene promoter. Biochem. Biophys. Res. Commun., 357, 8-13.
26. Ohtsu,H. et al. (2002) Antitumor agents. 217. Curcumin analogues as novel androgen receptor antagonists with potential as anti-prostate cancer agents. J. Med. Chem., 45, 5037-5042.
27. Lin,H.K. et al. (2002) Phosphorylation-dependent ubiquitylation and degradation of androgen receptor by Akt require Mdm2 E3 ligase. EMBO J., 21, 4037-4048.
28. Niu,Y. et al. (2008) Tissue prostate-specific antigen facilitates refractory prostate tumor progression via enhancing ARA70-regulated androgen receptor transactivation. Cancer Res., 68, 7110-7119.
29. Kuil,C.W. et al. (1995) Ligand-induced conformational alterations of the androgen receptor analyzed by limited trypsinization. Studies on the mechanism of antiandrogen action. J. Biol. Chem., 270, 27569-27576.
30. Zhang,H. et al. (2007) PC-1/PrLZ contributes to malignant progression in prostate cancer. Cancer Res., 67, 8906-8913.
31. Tyagi,R.K. et al. (2000) Dynamics of intracellular movement and nucleocytoplasmic recycling of the ligand-activated androgen receptor in living cells. Mol. Endocrinol., 14, 1162-1174.
32. Sheflin,L. et al. (2000) Inhibiting proteasomes in human HepG2 and LNCaP cells increases endogenous androgen receptor levels. Biochem. Biophys. Res. Commun., 276, 144-150.
33. Lin,H.K. et al. (2004) Regulation of androgen receptor signaling by PTEN (phosphatase and tensin homolog deleted on chromosome 10) tumor suppressor through distinct mechanisms in prostate cancer cells. Mol. Endocrinol., 18, 2409-2423.
34. Tsubuki,S. et al. (1996) Differential inhibition of calpain and proteasome activities by peptidyl aldehydes of di-leucine and tri-leucine. J. Biochem., 119, 572-576.
35. Nicholson,D.W. et al. (1995) Identification and inhibition of the ICE/ CED-3 protease necessary for mammalian apoptosis. Nature, 376, 37-43.
36. Miyamoto,H. et al. (2005) Inhibition of the Akt, cyclooxygenase-2, and matrix metalloproteinase-9 pathways in combination with androgen deprivation therapy: potential therapeutic approaches for prostate cancer. Mol. Carcinog., 44, 1-10.
37. Miyamoto,H. et al. (2005) Does androgen deprivation improve treatment outcomes in patients with low-risk and intermediate-risk prostate cancer? Nat. Clin. Pract. Oncol., 2, 236-237.
38. Wu,H.C. et al. (1994) Derivation of androgen-independent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int. J. Cancer, 57, 406-412.
39. Miyamoto,H. et al. (2007) Promotion of bladder cancer development and progression by androgen receptor signals. J. Natl. Cancer Inst., 99, 558-568.
40. Yang,Z. et al. (2007) ASC-J9 ameliorates spinal and bulbar muscular atrophy phenotype via degradation of androgen receptor. Nat. Med., 13, 348-353.
41. Lai,J.J. et al. (2009) Monocyte/macrophage androgen receptor suppresses cutaneous wound healing in mice by enhancing local TNF-alpha expression. J. Clin. Invest., 119, 3739-3751.
42. Wu,M.H. et al. (2010) Androgen receptor promotes hepatitis B virusinduced hepatocarcinogenesis through modulation of hepatitis B virus RNA transcription. Sci. Transl. Med., 2, 32ra35.
43. Gingrich,J.R. et al. (1996) A transgenic mouse prostate cancer model. Toxicol. Pathol., 24, 502-504.
44. Wang,R. et al. (2009) Transcription variants of the prostate-specific PrLZ gene and their interaction with 14-3-3 proteins. Biochem. Biophys. Res. Commun., 389, 455-460.
45. Evans,R.M. (1988) The steroid and thyroid hormone receptor superfamily. Science, 240, 889-895.
46. Kallio,P.J. et al. (1994) Agonists, but not antagonists, alter the conformation of the hormone-binding domain of androgen receptor. Endocrinology, 134, 998-1001.
47. Lin,H.K. et al. (2002) Proteasome activity is required for androgen receptor transcriptional activity via regulation of androgen receptor nuclear translocation and interaction with coregulators in prostate cancer cells. J. Biol. Chem., 277, 36570-36576.
48. Pickart,C.M. (2001) Mechanisms underlying ubiquitination. Annu. Rev. Biochem., 70, 503-533.
49. Wang,R. et al. (2007) PrLZ is expressed in normal prostate development and in human prostate cancer progression. Clin. Cancer Res., 13, 6040-6048.
50. van der Kwast,T.H. et al. (1991) Androgen receptors in endocrine-therapyresistant human prostate cancer. Int. J. Cancer, 48, 189-193.
51. Ruizeveld de Winter,J.A. et al. (1991) Androgen receptor expression in human tissues: an immunohistochemical study. J. Histochem. Cytochem., 39, 927-936.
52. Ruizeveld de Winter,J.A. et al. (1994) Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am. J. Pathol., 144, 735-746.